Regenerative wound healing via inflammation-modulating biomaterials
通过炎症调节生物材料实现伤口再生愈合
基本信息
- 批准号:8107808
- 负责人:
- 金额:$ 43.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAmphibiaBackcrossingsBedsBindingBiocompatible MaterialsBiologicalBiological AssayBiological MarkersBiomimetic MaterialsC57BL/6 MouseCartilageCell Culture TechniquesCell Cycle RegulationCell physiologyCell-Matrix JunctionCellsChemicalsChromosome MappingCicatrixClinicalCollaborationsComplexCoupledCytotoxic T-LymphocytesDegradation PathwayDoseEarEffectivenessEncapsulatedEnzymesFamilyFibroblastsFutureGlycolysisGoalsGrowthHealedHumanHydrogelsHydroxylationIn SituIn VitroInbreedingInflammationInflammation MediatorsInflammatoryInflammatory ResponseInjuryKineticsKnowledgeLaboratoriesLigationLiverLuciferasesMammalsMatrix MetalloproteinasesMediatingMediator of activation proteinMedicalMedicineMetabolicMetabolismMethodsModalityMolecularMouse StrainsMusNatural regenerationOrganOryctolagus cuniculusOutcomePathway interactionsPatient CarePeptidesPharmaceutical PreparationsPolymersProcessProcollagen-Proline DioxygenaseProteinsReactionReporterRoleSiteTestingTherapeutic AgentsTimeTissuesTopical agentToxic effectTranscriptional RegulationTranslatingUbiquitinationUp-RegulationWound Healingangiogenesisappendagebaseblastemacartilage regenerationdesignhealinghypoxia inducible factor 1in vivoinhibitor/antagonistinsightlimb regenerationmigrationmouse modelnovelprotein expressionreconstitutionregenerativeresponseskillssuccesstissue regenerationtranscription factorubiquitin-protein ligasewound
项目摘要
DESCRIPTION (provided by applicant): It is well known that prolonged inflammation hinders the optimal goal of wound repair, namely prompt closure of the wound with minimal scarring. However, the objective of tissue regeneration (as opposed to wound repair) is to reconstitute and replace damaged tissue with a functional biological replica of the lost tissue without scarring. In this latter case, the role of inflammation is not well established for the simple reason that most mammals including humans have rarely demonstrated any capacity for regeneration (with the exception of the liver) precluding experimental approaches. Based upon our preliminary observations in a mouse model of appendage injury, this proposal will address the possibility that enhancing at least some aspects of inflammation will re-direct wound healing towards regeneration. We will also examine the use of novel biomaterials to locally harness key aspects of the inflammatory response and facilitate tissue regeneration. Ear whole closure, as seen in rabbits and in the inbred MRL mouse strain is considered to be a mammalian example of regeneration similar to limb regeneration in amphibians. Ear holes close completely with the replacement of cartilage and without scarring. In this proposal, we present in-vitro and in-situ evidence that the wound site during this regenerative response is pro-inflammatory and that pharmacological up- regulators of inflammation induce regeneration in otherwise non-regeneration competent mice. Inflammation has been shown to be regulated by the transcription factor HIF1a and we will focus on HIF1a up-regulation in C57BL/6 mice to further explore its role in the regenerative response. Since HIF1a is modulated at the protein level and its degradation is initiated by hydroxylation accomplished by prolyl hydroxylases (PHDs), we will examine several inhibitors of HIF1a degradation including a PHD inhibitor, a direct HIF1a hydroxylation inhibitor and an inhibitor of ubiquination. These molecules will be screened for activity in HIF-luciferase reporter mice and their cells in-vitro as 1) topical agents or soluble injectants into the wound site or administered systemically and 2) coupled to a biomaterial. Given that HIF activity regulates as much as 10% of all cellular functions and especially the metabolic state and inflammation, it is important that HIF-activating drugs be present only at the wound site and in a controlled manner. Novel in- situ forming macromolecular biomaterials will be designed with the goal of fine control, both spatial and temporal, of HIF levels at the wound site. We envision that this approach of mimicking the complex tissue microenvironment of a healing wound will allow for biomaterial degradation accompanied by tissue regeneration, leading in the future to new clinical modalities for tissue regeneration.
PUBLIC HEALTH RELEVANCE: Achieving predictable regeneration of damaged tissues and organs is a major goal of medicine. By studying the remarkable ability of the MRL mouse to heal injuries and the role of inflammation in this process, we will gain insight into methods to help translate this knowledge into patient care. In particular, we will examine the role of implantable "smart" biomaterials that release regeneration-specific drugs that regulate metabolism and inflammation and are under biological control.
描述(由申请方提供):众所周知,长期炎症会阻碍伤口修复的最佳目标,即伤口迅速闭合,瘢痕形成最少。然而,组织再生(与伤口修复相反)的目的是重建受损的组织,并用功能性生物复制品替代丢失的组织,而不会留下疤痕。在后一种情况下,炎症的作用还没有很好地确定,原因很简单,大多数哺乳动物,包括人类,很少表现出任何再生能力(肝脏除外),排除了实验方法。基于我们在小鼠附件损伤模型中的初步观察,该提议将解决增强炎症的至少某些方面将重新引导伤口愈合朝向再生的可能性。我们还将研究使用新型生物材料来局部利用炎症反应的关键方面并促进组织再生。 如在兔和近交系MRL小鼠品系中所见,耳全闭合被认为是与两栖动物中的肢体再生类似的哺乳动物再生实例。耳孔完全关闭与软骨的替代和没有疤痕。在该提案中,我们提出了体外和原位证据,表明在这种再生反应期间的伤口部位是促炎性的,并且炎症的药理学上调剂在其他非再生能力小鼠中诱导再生。炎症已被证明是由转录因子HIF 1a调节,我们将集中在HIF 1a上调C57 BL/6小鼠,以进一步探讨其在再生反应中的作用。 由于HIF 1a在蛋白质水平上受到调节,并且其降解是通过脯氨酰羟化酶(PHD)完成的羟基化来启动的,因此我们将研究HIF 1a降解的几种抑制剂,包括PHD抑制剂,直接HIF 1a羟基化抑制剂和泛素化抑制剂。将在HIF-荧光素酶报告基因小鼠及其细胞中筛选这些分子的体外活性,作为1)局部药物或可溶性注射剂进入伤口部位或全身给药,以及2)与生物材料偶联。考虑到HIF活性调节多达10%的所有细胞功能,特别是代谢状态和炎症,重要的是HIF激活药物仅存在于伤口部位并以受控的方式存在。将设计新型原位形成的大分子生物材料,其目标是在空间和时间上精细控制伤口部位的HIF水平。我们设想,这种模拟愈合伤口的复杂组织微环境的方法将允许伴随组织再生的生物材料降解,从而在未来导致新的组织再生临床模式。
公共卫生相关性:实现受损组织和器官的可预测再生是医学的一个主要目标。通过研究MRL小鼠愈合损伤的非凡能力以及炎症在这一过程中的作用,我们将深入了解帮助将这些知识转化为患者护理的方法。特别是,我们将研究可植入的“智能”生物材料的作用,释放再生特定的药物,调节代谢和炎症,并在生物控制下。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ellen s. Heber-Katz其他文献
Ellen s. Heber-Katz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ellen s. Heber-Katz', 18)}}的其他基金
Regenerative wound healing via inflammation-modulating biomaterials
通过炎症调节生物材料实现伤口再生愈合
- 批准号:
8993948 - 财政年份:2015
- 资助金额:
$ 43.77万 - 项目类别:
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
(PQA2) 哺乳动物再生、高脂肪饮食和乳腺癌:共同的联系?
- 批准号:
9009892 - 财政年份:2013
- 资助金额:
$ 43.77万 - 项目类别:
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
(PQA2) 哺乳动物再生、高脂肪饮食和乳腺癌:共同的联系?
- 批准号:
9086307 - 财政年份:2013
- 资助金额:
$ 43.77万 - 项目类别:
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
(PQA2) 哺乳动物再生、高脂肪饮食和乳腺癌:共同的联系?
- 批准号:
8899472 - 财政年份:2013
- 资助金额:
$ 43.77万 - 项目类别:
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
(PQA2) 哺乳动物再生、高脂肪饮食和乳腺癌:共同的联系?
- 批准号:
8722513 - 财政年份:2013
- 资助金额:
$ 43.77万 - 项目类别:
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
(PQA2) 哺乳动物再生、高脂肪饮食和乳腺癌:共同的联系?
- 批准号:
8590786 - 财政年份:2013
- 资助金额:
$ 43.77万 - 项目类别:
Regenerative wound healing via inflammation-modulating biomaterials
通过炎症调节生物材料实现伤口再生愈合
- 批准号:
8258251 - 财政年份:2011
- 资助金额:
$ 43.77万 - 项目类别:
Regenerative wound healing via inflammation-modulating biomaterials
通过炎症调节生物材料实现伤口再生愈合
- 批准号:
8656970 - 财政年份:2011
- 资助金额:
$ 43.77万 - 项目类别:
Regenerative wound healing via inflammation-modulating biomaterials
通过炎症调节生物材料实现伤口再生愈合
- 批准号:
8454537 - 财政年份:2011
- 资助金额:
$ 43.77万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 43.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 43.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 43.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)